Cargando…
MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases
Acute hyperinflammatory virus infections, such as influenza or coronavirus disease-19, are still a major health burden worldwide. In these diseases, a massive overproduction of pro-inflammatory cytokines and chemokines (cytokine storm syndrome) determine the severity of the disease, especially in la...
Autores principales: | Ludwig, Stephan, Pleschka, Stephan, Planz, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091867/ https://www.ncbi.nlm.nih.gov/pubmed/36841033 http://dx.doi.org/10.1016/j.coviro.2023.101304 |
Ejemplares similares
-
Anti-viral approaches against influenza viruses
por: Pleschka, Stephan, et al.
Publicado: (2006) -
Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002
por: Hamza, Hazem, et al.
Publicado: (2021) -
Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients
por: Scheuch, Gerhard, et al.
Publicado: (2018) -
The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs
por: Schreiber, André, et al.
Publicado: (2022) -
Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
por: Koch-Heier, Julia, et al.
Publicado: (2022)